×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results
Business Wire
CEL-SCI to sign partnership agreement in Saudi Arabia—Potential for patient access and reimbursement/sale of Multikine in Saudi Arabia...
3 days ago
Cel-Sci: Fiscal Q3 Earnings Snapshot
Greenwich Time
VIENNA, Va. (AP) — VIENNA, Va. (AP) — Cel-Sci Corp. (CVM) on Thursday reported a loss of $5.7 million in its fiscal third quarter.
3 days ago
CEL-SCI files for breakthrough designation for Multikine in Saudi Arabia
MSN
CEL-SCI (CVM) announced that a Breakthrough Medicine Designation application has been filed with the Saudi Food and Drug Authority for Multikine in...
1 day ago
CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer
Yahoo Finance
Strong interest from Saudi investment funds in CEL-SCI, Multikine, and potential joint venture to address the wider Middle East and North...
1 month ago
CEL-SCI’s Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows for Patient Access and Reimbursement/Sale Upon Granting of the Designation Which Takes Approximately 60 Days Based on SFD
BioSpace
Memorandum of Understanding (MOU) signed with a leading Saudi Arabian pharma company which submitted the Breakthrough Medicine Designation...
4 days ago
Cel-Sci: Fiscal Q3 Earnings Snapshot
Norwalk Hour
VIENNA, Va. (AP) — VIENNA, Va. (AP) — Cel-Sci Corp. (CVM) on Thursday reported a loss of $5.7 million in its fiscal third quarter.
3 days ago
Cel-Sci: Fiscal Q3 Earnings Snapshot
Huron Daily Tribune
VIENNA, Va. (AP) — VIENNA, Va. (AP) — Cel-Sci Corp. (CVM) on Thursday reported a loss of $5.7 million in its fiscal third quarter.
4 days ago
CEO’s Bold Move: Major Investment in Cel-Sci Stock!
TipRanks
Cel-Sci's stock is significantly impacted by poor financial performance, with persistent losses and negative cash flows being major concerns.
3 weeks ago
CEL-SCI Announces Pricing of $5.7 Million Offering Priced At-the-Market Under NYSE American Rules
Yahoo Finance
VIENNA, Va., July 11, 2025--(BUSINESS WIRE)--CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE American: CVM), a clinical stage cancer...
1 month ago
CEL-SCI reports Q3 EPS ($1.36) vs. ($4.18) last year
TipRanks
Commercial and regulatory momentum for Multikine is accelerating due to three driving factors-our partnership negotiations in Saudi Arabia,...
3 days ago
